By Heather Hobbs
BRINGING YOU THE LATEST NEWS & EVENTS FROM THE SCIENCE INDUSTRY Award Recognises Exceptional Research in Biomedicine
The BIAL Foundation has announced the 3rd BIAL Award in Biomedicine open, with nominations accepted until 30th June 2023. The international award carries a €300,000 prize in recognition for work of a broad biomedical nature with exceptional quality and scientifi c relevance published in the last 10 years.
The winner will be chosen by an independent and international Jury chaired by Ralph Adolphs, Professor of Psychology, Neuroscience and Biology at Caltech (California Institute of Technology). In addition to the president, the Panel includes 12 members appointed by the European Research Council, the Council of Rectors of Portuguese Universities, the European Medical Association, the Scientifi c Board of the BIAL Foundation, previous winners of the BIAL Award and editors of the British Medical Journal and the New England Journal of Medicine.
Candidates for this award may be nominated by members of the Jury, members of the Scientifi c Board of the BIAL Foundation, previous BIAL Award winners, Scientifi c Societies, Boards or Deans of Medical Faculties, Heads of leading research institutes and Boards or Heads of prestigious Academies. Highly qualifi ed researchers may also nominate works, though self-nominations will not be accepted.
Ralph Adolphs, President of the Jury, expressed his high expectations for this new edition: “Given the broad nature of this award, we expect to receive nominations from organised groups of scientists with a wide range of affi liations, including in academia, scientifi c societies and research institutes. We hope to receive works of high quality and relevance from scientists from any country around the world and at any stage of their career.”
For Luís Portela, Chairman of the BIAL Foundation. “this award aims to mobilise the scientifi c community to share, through nominations, relevant work by researchers from all over the world, with a view to recognising the most important scientifi c discoveries in the biomedical fi eld.”
In the last edition in 2021, this award distinguished an article published in Nature journal in 2017 focused on the mRNA technology used in Pfi zer-BioNTech and Moderna’s Covid-19 vaccines. The winning team was led by the American scientist Drew Weissman and included, at the time of the article’s
Professor Ralph Adolphs Dr Drew Weissman, lead and
representative of the team award winners in 2021 for their work: ‘Zika virus protection by a single low-dose nucleoside-modifi ed mRNA vaccination’. Published in Nature.
publication, 36 co-authors from the Universities of Pennsylvania, Duke and Kansas State (USA), Harvard Medical School (USA), National Institutes of Health (USA), Bioqual Inc. (USA), Acuitas Therapeutics (Canada), and BioNTech RNA Pharmaceuticals (Germany).
Created in 1994 the BIAL Foundation aims to foster the scientifi c study of human beings in different areas and the award in Biomedicine is one of the biggest European awards in this fi eld. The BIAL Award in Biomedicine takes place biannually, alternating with the Prémio BIAL de Medicina Clínica. It has the patronage of the President of the Portuguese Republic, the Council of Rectors of Portuguese Universities and the European Medical Association.
Further details of the Regulation and Nomination Form for the BIAL Award in Biomedicine 2023 can be found on the link below.
More information online:
ilmt.co/PL/w14j 60320pr@reply-direct.com
Grants take Functional 3Rs Technologies Forward
NC3Rs has awarded £90K for two collaborative projects focused on cell-based models of disease for functional genomic screens that can be applied more confi dently in industry to identify and validate potential new therapeutic targets.
The T2T funding scheme acts to accelerate uptake of new models and tools into industry by offering NC3Rs grant holders the opportunity to develop a collaborative project with the Milner Technology Institute (MTI) and apply their CRISPR gene editing approaches to create human-relevant models of disease for drug development. Each award is complemented with matched in-kind contributions from the MTI, including access to their functional genomics facilities, expertise and industry networks.
Dr Anthony Holmes, NC3Rs Director of Science and Technology, said: “These awards will help increase the reach and impact of NC3Rs-funded project outputs and have the potential to support the pharmaceutical industry in identifying new disease targets in human model systems. There is still much work to be done to get to that stage, but by applying MTI’s functional genomics capabilities to models we have funded the development of, we hope to accelerate that process and maximise the 3Rs impacts of our investment.”
More information online:
ilmt.co/PL/x1Ky 60349pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188
